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Abstract Intensive chemotherapy directed against acute mye-
loid leukemia of childhood is followed by profound neutrope-
nia and high risk for bacterial and fungal infections, including
viridans group streptococci as a common cause for gram-
positive septicemia. Few retrospective studies have shown the
efficacy of various antibiotic prophylactic regimens in children.
We retrospectively studied 50 pediatric patients treated on the
AML-BFM 2004 protocol between 2005 and 2015 at St. Anna
Children’s Hospital and assessed the effect of antibiotic prophy-
laxis on the frequency of febrile neutropenia and bacterial sep-
sis. Fifty pediatric patients underwent 199 evaluable chemo-
therapy cycles. Viridans sepsis occurred after none of 98 cycles
with prophylactic administration of teicoplanin/vancomycin in
comparison to 12 cases of viridans sepsis among 79 cycles
without systemic antibacterial prophylaxis (0 vs. 15 %,
p < 0.0001). In addition, there were significantly fewer
episodes of febrile neutropenia in the teicoplanin/vancomycin
group (44 % vs. no prophylaxis 82 %, p < 0.0001). Severity of
infection seemed to be worse when no antibiotic prophylaxis
had been administered with a higher rate of intensive care unit
treatment (0/98, 0 %, vs. 4/79, 5 %, p = 0.038). So far, no
increase of vancomycin-resistant enterococcus isolates in
surveillance cultures was noticed. Antibiotic prophylaxis with
teicoplanin (or vancomycin) appears safe and feasible and
resulted in eradication of viridans sepsis and decreased
incidence of febrile neutropenia in pediatric AML patients.
The possibility to administer teicoplanin on alternate days on
an outpatient basis or at home could contribute to patient’s
quality of life and decrease health care costs.
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Introduction
Acute myeloid leukemia (AML) of childhood and adoles-
cence accounts for 20 % of pediatric leukemias. Cure rates
are lower in comparison to those in acute lymphoblastic
leukemia [1]. Yet, intensive chemotherapy based mainly on
anthracyclines and purine analogues has improved outcome
over the last decades [1–3]. Profound and prolonged neutro-
penia following intensive chemotherapy cycles, however, is
associated with a high risk for bacterial and fungal infections
contributing to considerable therapy-associated morbidity and
mortality [4, 5]. Among the different pediatric AML study
groups, the main cause of treatment-related death following
induction is infection—between 5 and 15 % of the patients
have been reported to die from infectious complications [6–8].
Viridans group streptococci (VGS) are a common cause for
sepsis and pneumonia in neutropenic patients. According to
data from study AML-BFM 93 and 2004, VGS was isolated
in more than 20 and 30 % of cases with neutropenic bacte-
remia, respectively. While incidence of VGS sepsis was
significantly higher after chemotherapy cycles containing
high-dose cytarabine in protocol AML-BFM 93, this differ-
ence was not obvious in the 2004 study [4, 9]. Infection with
VGS bears substantial risk for viridans streptococcal shock
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syndrome with a reported mortality rate of up to 100 % [10].
High morbidity and mortality associated with neutropenic in-
fections have caused long-standing discussions about antibi-
otic prophylactic regimens for pediatric AML patients [11]. At
St. Jude Children’s Research Hospital, a prophylactic regimen
of intravenous (iv) cefepime or iv vancomycin plus either oral
cephalosporine, oral cipropfloxacine or iv cefepime has been
applied to neutropenic pediatric AML patients [12]. A reduc-
tion of (VGS) septicemia and hospitalization days could be
demonstrated with this approach; however, incidence of fe-
brile neutropenia was similar, as recently published in an up-
date to the original study [12, 13]. As vancomycin has to be
administered at least every 12 h iv to obtain adequate blood
levels, this prophylactic regimen either requires hospitaliza-
tion or at-home administration by trained caregivers.
Teicoplanin is a glycopeptide antibiotic with long elimina-
tion half-life that is usually administered once daily. However,
an alternate-day dosing schedule with administration three
times a week (for example, Monday-Wednesday-Friday) on
an outpatient basis has been studied in patients with chronic
osteomyelitis or endocarditis and resulted in comparable and
adequate serum concentrations [14–16].
We report now our results on the use of prophylactic out-
patient administration of teicoplanin (or vancomycin in case
of admission to hospital) in neutropenic pediatric AML pa-
tients in order to reduce febrile neutropenia, bacterial sepsis,
and VGS sepsis, in particular.
Materials and methods
Patients
Between May 2005 and July 2015, 50 consecutive pediatric
patients with AML (male n = 25, age 0.2–17.9, median
7.6 years) were enrolled into trial AML-BFM 2004 at St.
Anna Children’s Hospital in Vienna. The initial diagnosis of
AML and assignment to subtypes were done according to the
FAB and WHO classification (FAB M0 n = 3, M1 n = 2, M2
n = 16, M3 n = 7, M4 n = 6, M5 n = 8, M7 n = 6, NA n = 2—
one patient with myelosarcoma, one with secondary AML)
[17, 18]. After confirmation of diagnosis, parental or patient
informed consent for data registration and follow-up was
obtained in all patients according to local laws and
regulations. All investigations had been approved by the
Institutional Ethics Committees.We performed a retrospective
chart review of these 50 patients and collected data on use of
antibiotics as well as incidence and severity of infection. Data
were not collected after relapse or stem cell transplant.
Courses during which a patient received antibiotics at the start
of chemotherapy due to documented infection (or suspected
infection in case of nonneutropenic fever along with
chemotherapy) were excluded from our analysis.
AML treatment
The aim of AML-BFM 2004 protocol (Eudract-Nr. 2006-
004710-41, NCT00111345) was to evaluate in two randomi-
zations if the prognosis of childhood AML could be further
improved by therapy intensification (see supplemental Table 1
for chemotherapy details). Liposomal daunorubicin was im-
plemented in first induction in a theoretically higher dosage
than idarubicin (first randomization, course ADxE), and 2-
CDAwas evaluated as intensification in consolidation therapy
for high-risk (HR) patients (second randomization, course AI/
2-CDA) [19]. In May 2010, randomizations were closed and
all patients received induction with ADxE and consolidation
with AI/2-CDA in the HR group [20]. Patients with Down
syndrome were treated according to standard risk (SR) group;
however, induction with AIE was continued and etoposide in
intensification (HAE) was omitted. Cytarabine dose varied
between the different courses (see supplemental Table 1):
while a low dose of cytarabine was administered during in-
duction (ADxE, AIE: total dose of 1.400 mg/m2, first 48-h
continuous administration, then every 12 h), patients received
high-dose cytarabine during courses HAM, HAE, and HA
(total dose 18.000 mg/m2). In course haM, an intermediate
dose of 6000 mg/m2 cytarabine (1000 mg every 12 h over
3 days) was administered. The total dose of cytarabine in
courses AI and AI/2-CDA was 2000 mg/m2; however, this
dose was administered as a continuous infusion of 500 mg/
m2/day over 4 days. Previous studies have shown that
cytarabine as continuous infusion is associated with higher
antileukemic efficacy but also increased grade 3/4 toxicity rate
in comparison to daily short-term infusion [21]. Hence, we
combined cycles haM and AI/AI/2-CDA to the intermediate
dose group for analysis.
Supportive care
Different prophylactic antibiotic regimens were used within
the study period at St. Anna Children’s Hospital to prevent
treatment-associated bacterial sepsis in general and VGS
sepsis in particular. While most patients did not receive any
antibiotic prophylaxis in the early years, prophylactic regi-
mens consisting of oral penicillin or iv piperacillin/
tazobactam or other combinations were administered later,
however, inconsistently. In 2008, we commenced a prophy-
lactic regimen with teicoplanin which was administered to
almost all patients from the second half of 2009 on. The
prophylactic regimen was started after myelosuppressive
chemotherapy at the onset of severe neutropenia (absolute
neutrophil count (ANC) ≤ 500/μl); teicoplanin was adminis-
tered at a dose of 15–20 mg/kg iv on alternate days in our
outpatient clinic or by oncologic nurses of our external nurs-
ing service at home until ANC increased to more than 500/μl.
Dosing on alternate days was only applied as part of the
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prophylactic regimen. In case of admission to the hospital
(due to fever or other reasons), vancomycin at a standard dose
of 40 mg/kg/day iv was usually given instead of teicoplanin
for cost reasons. Teicoplanin/vancomycin prophylaxis was
combined with piperacillin/tazobactam or oral ciprofloxacin
in few cases. Vancomycin or teicoplanin serum levels were
only assessed in selected cases such as renal impairment.
All patients received continuous Pneumocystis jirovecii
prophylaxis with trimethoprim-sulfamethoxazole three times
per week as well as oral nonabsorbable amphotericin B as
candida prophylaxis and paromomycin for enteral decontami-
nation. Systemic fungal prophylaxis with itraconazole,
voriconazole, or liposomal amphotericin was administered
during neutropenia. During neutropenic phases, the use of
antiseptic mouthwash was advised. Administration of
granulocyte-colony-stimulating factor (G-CSF) was not recom-
mended. Febrile neutropenia was defined as a body temperature
of greater than 38.0 °C that persisted for an hour or a single
temperature of ≥38.5 °C combined with neutropenia. A
diagnosis of bacterial sepsis required positive blood culture
and systemic clinical signs of infection. Bacterial blood cultures
were routinely obtained from patients presenting with fever or
other signs of infection. Samples obtained from all lumina of
the central venous catheter were inoculated into three culture
vials (BD BACTEC Plus Aerobic/F, Plus Anaerobic Plus,
Mycosis IC/F, Becton, Dickinson and Company, Sparks,
USA). Peripheral blood cultures were not routinely obtained.
Toxicity grade of fever was defined based on the Common
Terminology Criteria for Adverse Events v3.0, available online
at http://ctep.cancer.gov/forms/. In case of fever, patients were
admitted to the hospital and empiric broad-spectrum antibiotics
(in most cases piperacillin/tazobactam in combination with
aminoglycoside and glycopeptide) were started. Prophylactic
or empiric administration of glycopeptides was mostly contin-
ued in case of negative gram-positive blood cultures. Routine
surveillance conventional stool cultures were taken from all
patients in the beginning of treatment and during follow-up.
Statistical analysis
Fisher’s exact test and Wilcoxon test were used to com-
pare courses without antibiotic prophylaxis and courses
with teicoplanin/vancomycin prophylaxis. The statistical
analysis was done with SAS System V9.2 (2008, SAS
Institute, Cary, NC). All p values below 0.05 were
considered significant.
Results
Fifty patients were included in our study. Of these, 17 were
treated according to the SR group and 31 according to HR
arm. Of the remaining two, one patient with AML M3
received only an induction course with ADxE and continued
therapy with ATRA and arsen trioxide only, while the other
patient was diagnosed with secondary AML following treat-
ment for acute lymphoblastic leukemia and received one
course containing liposomal daunorubicin and fludarabine,
followed by one course AI-2CDA, which was evaluated for
our study. In total, 50 patients underwent 209 chemotherapy
cycles, 10 of which (5 %) were excluded from our analysis
(due to administration abroad n = 1, antibiotic treatment al-
ready along with chemotherapy n = 9). Of 199 evaluable
courses, 42 contained low-dose cytarabine (ADxE n = 22,
AIE n = 20), 89 intermediate-dose cytarabine (haM n = 43,
AI n = 27, AI/2-CDA n = 19), and 68 high-dose cytarabine
(HAM n = 29, HAE n = 34, HA n = 5, Table 2).
Ninety-eight of evaluable chemotherapy courses (49 %)
were given with antibiotic prophylaxis using teicoplanin/
vancomycin (± other: piperacillin/tazobactam n = 6, oral cip-
rofloxacin n = 7). Notably, 85/98 courses were primarily
teicoplanin-based, whereas during 13 courses, only vancomy-
cin and no teicoplanin was given. No systemic antibiotic pro-
phylaxis was administered following 79 evaluable chemother-
apy courses (40 %). Twenty-two additional courses were re-
corded with various prophylactic regimens: seven courses
were given with oral penicillin, ten courses with daily
piperacillin/tazobactam iv, and in the remaining five courses,
other antibiotic combinations were administered. As the latter
three groups were rather small and inhomogeneous, they were
excluded from statistical analysis and only the large two
groups (no prophylaxis and teicoplanin/vancomycin prophy-
laxis) were statistically compared.
Results of infectious episodes according to prophylaxis
regimen are shown in Table 1: of 98 cycles with prophylaxis
with teicoplanin/vancomycin, no patient developed VGS sep-
sis in comparison to 12 cases of VGS sepsis among 79 cycles
without antibiotic prophylaxis (0 vs. 15 %, p < 0.0001). In
addition, also episodes of total febrile neutropenia were
significantly less frequent in the teicoplanin/vancomycin
group (44 % vs. no prophylaxis 82 %, p < 0.0001). In 53 of
79 cycles (67 %) without primary antibiotic prophylaxis,
vancomycin/teicoplanin was administered with occurrence
of febrile neutropenia or other clinical signs of infection.
Altogether, we recorded 25 episodes (in 20 patients) of
culture-proven bacterial sepsis during the 199 courses
(13 %). Gram-positive bacteria were isolated in 60 % (total
n = 15, VGS n = 14, Staphylococcus epidermidis n = 1). One
patient even had two episodes of VGS sepsis during intensive
chemotherapy. Gram-negative septicemias occurred in 40 %
(total n = 10, E. coli n = 4, Pseudomonas aeruginosa n = 4,
Klebsiella pneumoniae n = 1, Fusobacteria n = 1). Of these
25 bacterial sepsis episodes, 13 occurred during courses with-
out antibiotic prophylaxis, ten after administration of
teicoplanin/vancomycin prophylaxis (all gram-negative bac-
teria), and two episodes of VGS sepsis occurred despite
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prophylaxis with oral penicillin. Hence, the mere sepsis rate
was not significantly different between courses with
teicoplanin/vancomycin prophylaxis and without antibiotic
prophylaxis (p = 0.26, see Table 1). Sepsis started on average
on day 15 from beginning of chemotherapy cycle after
teicoplanin/vancomycin prophylaxis (median day 15, range
9–19) and on day 14 when no prophylaxis was administered
(median 14, range 11–18; p = 0.32).
Life-threatening complications occurred in five cases of
bacterial sepsis (20 %), causing admission to intensive care
unit (ICU) for treatment—in two of these episodes, VGS were
isolated. In total, 14 % of patients with VGS sepsis (2/14) had
to be treated at ICU. No patient in the study period died from
infectious complications. Interestingly, severity of infection
seemed to be worse in case of febrile neutropenia when no
antibiotic prophylaxis had been administered with significant-
ly more days of fever and higher rate of treatment at ICU
(teicoplanin/vancomycin: median 2 days of fever, mean 3.7
vs. no prophylaxis: 4 and 6.1 days, p < 0.0001; ICU 0/98 [0 %]
vs. 4/79 [5 %], p = 0.038).
We also compared sepsis rate and febrile neutropenia with-
in the different cytarabine dose level subgroups. After
intermediate-dose cytarabine courses, VGS sepsis occurred
in 10 % (9/89) and in 7.4 % after high-dose courses (5/68,
p = not significant), whereas no VGS case was found after the
first induction (Table 2). The effect of teicoplanin/vancomycin
prophylaxis appeared most impressing in the intermediate-
dose group, resulting in a significantly lower rate of VGS
sepsis (0 vs. 24 %, p = 0.0004) and febrile neutropenia (39
vs. 86 %, p < 0.0001) compared to no prophylaxis. However,
a trend toward fewer VGS episodes (0 vs. 13 %, p =NS) and
definitely also regarding less frequent febrile neutropenia (43
vs. 79 %, p = 0.008) was also seen in the high-dose cytarabine
group. Only following the first induction course that the rate
of febrile neutropenia was similar, whether teicoplanin/
vancomycin prophylaxis was given or not (60 vs. 78 %,
p = 0.45).
Data from hygiene surveillance were available until the end
of 2015 for vancomycin-resistant enterocci (VRE) and the end
of 2012 for VGS: routine surveillance stool cultures showed a
low incidence of VRE isolates in our hospital (32 of 2071
isolates from 2006 to 2015, 1.5 %). In total, 797 enterococcus
strains were isolated within the oncology department, 14 were
vancomycin resistant (1.8 %). Only one of these 14 cultures
was isolated from a patient with (secondary) AML following
treatment for acute lymphoblastic leukemia (ALL). In this
patient, surveillance cultures were already positive for the
same VRE isolate with beginning of ALL therapy and can
hence not be associated with our antibiotic prophylaxis.
Altogether, we did not appreciate a rise in VRE incidence in
the oncology department since the commencement of our pro-
phylactic regimen with teicoplanin/vancomycin since 2008
(five VRE isolates between 2006 and 2009, five VRE isolates
between 2009 and 2012, four VRE isolates between 2013 and
2015). Among all VGS isolates in the hospital (n = 750 be-
tween 2006 and 2012), not a single strain with teicoplanin or
vancomycin resistance was detected. Of 88 strains which were
tested for oral penicillin resistance, 19 were resistant (22 %).
Discussion
Intensive chemotherapy followed by profound and prolonged
neutropenia harbors a substantial risk for infectious complica-
tions among pediatric patients with AML [1, 8]. In particular,
infection with VGS has been reported as a major cause for
sepsis and pneumonia associated with considerable morbidity
with high rates of ICU admission and even mortality in this
cohort [4, 8, 22]. In order to prevent neutropenic sepsis, and
VGS sepsis in particular, different approaches in terms of an-
tibiotic prophylaxis have been considered [11, 23]. The
Oregon Health and Science University retrospectively studied
the use of iv vancomycin and ceftazidime and later iv cefe-
pime mono and could demonstrate low rates of infection and












p value Absolute days of
fever >38Ca
(median/mean)







No prophylaxis 79 12 (15) <0.0001 13 (16) NS 65 (82) <0.0001 4/6.1 <0.0001 2/2 4 0.038
Teico/vanco± 98 0 10 (10) 43 (44) 2/ 3.7 2/2 0
Penicillin po 7 2 (29) 2 (29) 4 (57) 4/4.5 2/2 1
Piperacillin/
tazobactam
10 0 0 4(40) 4/3.8 1.5/ 1.5 0
Other 5 0 0 0 NA NA 0
Total 199 14 25 116 4/5.1 2/2 5
NS not significant
a In case of febrile neutropenia
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VGS sepsis, in particular [24]. At St. Jude Children’s
Research center, a prophylactic regimen combining iv vanco-
mycin with oral ciprofloxacin or a cephalosporin has been
administered to pediatric AML patients in neutropenia. This
regimen resulted in reduction of incidence of VGS septicemia
and hospitalization days, however not of febrile neutropenia
episodes [12, 13]. One disadvantage of vancomycin is a short
half-life with the need of administration at least every 12 h
over 1 to 2 h. In comparison, teicoplanin is a glycopeptide
antibiotic with similar antibacterial spectrum and longer
half-life that is usually administered once a day (6 mg/kg/
day following a loading dose) iv shot. However, several pre-
vious studies used teicoplanin in a higher single dose (15–
20 mg/kg/day) on alternate days/three times a week with sim-
ilar clinical effectiveness and serum concentrations [14, 15].
In this retrospective analysis, we studied the effect of a pro-
phylactic regimen with iv teicoplanin on alternate days (daily
iv vancomycin in case of hospital admission) compared to no
prophylactic antibiotics in a group of 50 pediatric AML pa-
tients who were treated on the AML-BFM 2004 protocol be-
tween 2005 and 2015. Prophylaxis with teicoplanin/
vancomycin resulted in dramatic and significant decrease of
VGS sepsis compared to no antibiotic prophylaxis (0/98, 0 %,
vs. 12/79, 15 %, p < 0.0001) and significant reduction of fe-
brile neutropenia episodes (43/98, 44 %, vs. 65/79, 82 %,
p < 0.0001) and absolute fever days (p < 0.0001). This effect
was also visible in the intermediate-dose cytarabine subgroups
with significantly lower rate of VGS sepsis and febrile neu-
tropenia following teicoplanin prophylaxis (0 vs. 24 %,
p = 0.0004; 39 vs. 86 %, p < 0.0001; Table 2) and in the high-
dose cytarabine subgroup for reduction of febrile neutropenia
(43 vs. 79 %, p = 0.008). Of course, results in these subgroups
have to be regarded with caution due to small numbers. Hence,
our study supports the effectiveness and feasibility of preven-
tive antibiotics in neutropenic pediatric AML patients.
High-dose cytarabine has been frequently claimed a risk
factor for VGS sepsis in AML patients [25]. Retrospective
data from study AML-BFM 93 indeed demonstrated a signif-
icantly higher VGS sepsis rate following high-dose cytarabine
cycles whereas in a recent NOPHO-AML study and in the
AML-BFM 2004 study, no significant difference of VGS sep-
sis rate was observed between lower-dose and high-dose
courses [4, 9, 22]. In our study, rate of VGS sepsis was com-
parably high following intermediate-dose and high-dose cy-
cles (9.3 and 7.4 %) while no VGS sepsis occurred after in-
duction cycles with low-dose cytarabine.
VGS sepsis is known be associated with considerable
morbidity and in case of viridans streptococcal shock syn-
drome high mortality [10]. VGS sepsis was found to be
significantly more life-threatening in comparison to other
infections according to data from the Children’s Cancer
Group [25]. Recent data from international study groups
also describe a high incidence of life-threatening compli-
cations, i.e., ICU admission, associated with VGS sepsis:
while AML-BFM 2004 reported that 9.8 % of patients
with VGS sepsis needed intensive care treatment, inci-
dence of ICU treatment of VGS cases was 11.6 % within
the NOPHO group [9, 22]. Life-threatening shock was
observed in 13 % of neutropenic pediatric patients with
VGS sepsis. In our retrospective study, 14 % of cases with
VGS sepsis needed ICU treatment. With teicoplanin/
vancomycin prophylaxis, we could see a significant re-
duction of incidence of ICU treatment in comparison to
no prophylaxis (0/98, 0 %, vs. 4/79, 5 %, p = 0.038).




























No 18 0 NA 0 NA 14 (78) NS 8/8.9 (1–19) NS 2/2.2 2 NS
Teico/vanco ± 15 0 0 9 (60) 3/5.7 (1–15) 2/2 0
Other 9 0 0 3 (33) 5/4.3 1/1.3 0






No 37 9 (24) 0.0004 10 (27) NS 32 (86) <0.0001 4/5.5 (1–21) <0.0001 2/1.9 1 NS
Teico/vanco± 46 0 6 (13) 18 (39) 2/2.9 (1–9) 2/2 0
Other 6 0 0 2 (33) 5.5/5.5 2.5/2.5 0





No 24 3 (13) NS 3 (13) NS 19 (79) 0.008 4/5 0.003 2/2.1 1 NS
Teico/vanco± 37 0 4 (11) 16 (43) 3/3.3 2/2.2 0
Other 7 2 (29) 2 (29) 3 (43) 2/3 1/1.7 1
Total 68 5 (7) 9 (13) 38 (56) 3.5/4.1 2/2.1 2
NS not significant, NA not applicable
a In case of febrile neutropenia
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VGS prophylaxis with oral penicillin G for AML patients
has been frequently discussed and was administered during
seven chemotherapy cycles of our study period as well [23].
Although the numbers are small and have to be regarded with
caution, rate of febrile neutropenia with penicillin prophylaxis
was rather high (4/7, 57 %). More importantly, two patients
developed VGS sepsis despite oral penicillin prophylaxis, of
which one patient had to be treated at ICU for almost 2 weeks
as she developed pneumonitis and cardiac insufficiency. In
both cases, the antibiogramm demonstrated resistance to pen-
icillin. According to hygienic surveillance data at St. Anna
Children’s Hospital, 22 % of isolated VGS showed in vitro
resistance to oral penicillin; however, rates of up to 40 % have
been reported in other studies [22, 26]. Hence, VGS prophy-
laxis with oral penicillin cannot be generally recommended.
Among 98 patients of our study who received
teicoplanin/vancomycin prophylaxis, 10 % developed bac-
terial sepsis, all with gram-negative bacteria. In contrast,
bacterial sepsis among the patients without antibiotic pro-
phylaxis was mainly associated with gram-positive bacte-
ria/VGS. Hence, we considered if gram-negative sepsis
might have been prevented in the group without antibiotic
prophylaxis by early administration of broad-spectrum an-
tibiotics with emerging VGS sepsis. However, our data
show that sepsis occurred on similar days within the two
groups (average/median: no prophylaxis: day 14/14,
teicoplanin/vancomycin: day 15/15) which argues against
this assumption. Hence, due to considerable morbidity of
gram-negative sepsis, combination of teicoplanin/
vancomycin with an antibiotic covering gram-negative
spectrum should be considered.
Frequent handling of central venous catheters, even by
trained caregivers in a home infusion setting, bears the risk of
catheter-associated bloodstream infections. When patients were
not admitted to our hospital, teicoplanin was administered on
alternate days/three times per week iv shot either in our outpa-
tient clinic or by nurses of our external oncologic nursing ser-
vice at the patient’s home, resulting in minimal necessity to
handle central catheters. Another major advantage of adminis-
tration of antibiotics on an outpatient basis or even at home is a
decreased need to stay in the hospital with increase in patient’s
quality of life along with expected lower health care costs.
A major concern with application of antibiotic prophylaxis
is the emergence of resistant bacteria strains. Patients with
hematological malignancies are more prone to colonization
and infection with VRE due to the routine use of broad-
spectrum antibiotics, and antibiotic options in case of infection
with VRE are limited [27]. Data from St. Jude Hospital dem-
onstrated a higher incidence of VRE isolates in rectal cultures
among the group that received prophylactic antibiotic therapy
with intravenous vancomycin (± cefepime, ciprofloxacin, oral
cephalosporin) with five episodes of VRE bacteremia [13].
Since the introduction of our prophylactic regimen with
teicoplanin/vancomycin, we did not appreciate an increase in
VRE isolates in our oncology department at St. Anna
Children’s Hospital. Our data even show that many patients
without primary glycopeptide prophylaxis eventually received
glycopeptides as preemptive therapy in case of septicemia
(67 % of all nonprophylaxis cycles). This might add to a
potential selection pressure onVRE albeit not preventingmor-
bidity from VGS. However, the incidence of resistant bacteria
strains and possible higher incidence of fungal infections with
antibiotic prophylaxis have to be closely monitored in the
future. Benefits of antibiotic prophylaxis need to be continu-
ously balanced against negative effects of such a regimen.
There are limitations to our study: we did not randomly
assign patients to receiving teicoplanin/vancomycin prophy-
laxis or not but performed a retrospective chart review to doc-
ument infections. Prospective controlled randomized studies,
preferably involving multiple international institutions due to
the low absolute number of pediatric AML patients, are need-
ed in the future to confirm our results.
Conclusions
Antibiotic prophylaxis with teicoplanin (or vancomycin) ap-
pears safe and feasible and resulted in dramatic reduction of
VGS-associated sepsis and decreased incidence of febrile neu-
tropenia in neutropenic pediatric patients with AML. The pos-
sibility to administer teicoplanin on alternate days on an out-
patient basis or at home could contribute to patient’s quality of
life and decrease health care costs. Multi-institutional studies
are needed to evaluate this prophylactic regimen in a larger
cohort and acquire more data on the development of possible
bacterial resistance.
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